METAP1 and breast cancer: In human breast cancer cells METAP1 or METAP2 knockdown in combination with BEZ treatment reduced cell growth significantly better than knockdown alone but not significantly better than PI3K-inhibitor treatment alone, comparable with shRenilla control cells (Figure 5C).